Introduction {#s02}
============

The HIV-1 virus expresses a trimeric envelope glycoprotein (Env) on its surface. Env is a highly variable protein that is shielded from antibody recognition by recessed neutralization-sensitive epitopes and by a large number of host glycans that are attached to Env during its biosynthesis in infected cells ([@bib155]; [@bib149]).

The human immune system has evolved to tolerate and specifically avoid attacking self-glycans, making this form of shielding particularly effective. Nevertheless, a fraction of HIV-1--infected individuals develop antibodies that can neutralize diverse viral isolates by binding to Env. The observation that such antibodies arise during natural infection ([@bib6]; [@bib21]; [@bib76]; [@bib115]; [@bib127]; [@bib41]; [@bib57]; [@bib112]) and that they can block infection in experimental animal models ([@bib28]; [@bib29]; [@bib83], [@bib84]; [@bib124]; [@bib1]; [@bib103]; [@bib52],[@bib53], [@bib54]; [@bib2]; [@bib91]; [@bib105]) suggests that antibody-based vaccines for HIV-1 may be an attainable goal. Indeed, initial efforts to produce HIV-1 vaccines focused on immunization with recombinant Env proteins, but preclinical and clinical observations diminished the enthusiasm for this approach.

Numerous efforts to elicit broadly neutralizing antibodies (bNAbs) in experimental animals including guinea pigs, rabbits and monkeys using Env proteins, or Env-expressing viral vaccine vectors, were unsuccessful (reviewed in [@bib85] and [@bib129]). In most cases, Env-based immunogens elicit antibodies that neutralize laboratory-adapted tier 1 viruses and/or the autologous virus expressing the Env variant used for immunization, but they fail to neutralize heterologous primary isolates. Recently, well-ordered soluble trimers that more faithfully mimic the native HIV-1 spike have also been tested as immunogens in several different animal models ([@bib67]; [@bib80]; [@bib114]; [@bib101]; [@bib18]; [@bib58]; [@bib123]; [@bib46]; [@bib61]; [@bib69]). Although these recently developed native-like trimers produce more consistent neutralizing antibody responses to the corresponding autologous tier 2 viruses, they too failed to elicit bNAbs.

The challenge of eliciting bNAbs by vaccination was also illustrated in human trials (VAX003 and 004) wherein healthy volunteers were immunized with recombinant monomeric gp120 proteins ([@bib31]; [@bib106]). Although these vaccines elicited type-specific neutralizing antibodies, they failed to produce antibodies that neutralized heterologous primary HIV-1 isolates, and there was no protection from infection ([@bib31]; [@bib106]). More recently, the RV144 trial used a prime-boost regimen consisting of four priming injections with a recombinant canarypox vector genetically engineered to express HIV-1 Env, gag, and protease (ALVAC-HIV) and two boosters with a combination of two recombinant gp120s (AIDSVAX B/E). This regimen produced modest levels of protection, but again failed to elicit significant antibody-neutralizing activity against heterologous tier 2 strains of HIV-1 ([@bib108]; [@bib92]). Finally, a vaccine regimen consisting of three DNA prime injections with six plasmids encoding clade B gag, pol, and nef and three gp120 Envs from clade A, B, and C and a boost with a recombinant adenovirus-5 vector expressing the same Envs and a clade B gag-pol fusion protein also failed to elicit bNAbs and did not protect against infection ([@bib48]).

To better understand bNAb responses to HIV-1 Env, several monoclonal antibodies (MAbs) were isolated from chronically infected individuals, and their epitope specificities were characterized ([@bib152]; [@bib13]). However, the serum concentration of the first-generation bNAbs required to prevent infection in experimental animal models was so high that achieving this level by immunization seemed unlikely ([@bib82]; [@bib97]).

The failure to elicit bNAbs by immunization by Env immunogens and the relative lack of potency of the best available antibodies shifted the focus of HIV-1 vaccine research away from antibody-based vaccines toward T cell--based protection. Unfortunately, the two clinical trials of T cell--based vaccination conducted to date were ineffective at preventing infection and controlling viral load (HVTN502 \[Step study\] and HVTN503 \[Phambili study\]; [@bib12]; [@bib42]). In fact, there was even evidence of increased infection by HIV-1 in the Step study ([@bib26]).

In this review, we focus on the recent progress in HIV-1 vaccine development, in particular on the insights gained from cloning anti--HIV-1 antibodies from single memory B cells, how the new concepts are being tested, and what the results may mean for attaining the goal of HIV-1 vaccination.

First-generation monoclonal anti--HIV-1 antibodies {#s03}
==================================================

Polyclonal antibodies that neutralize more than just one HIV-1 strain were found in immunized guinea pigs as early as 1990; however, neutralization activity was limited ([@bib65]). Subsequent work extended these findings by uncovering antibodies from infected individuals with greater breadth and potency by phage display or by producing immortalized B cell lines. The most potent among the first-generation of human MAbs to HIV-1, b12, 2F5, 4E10, 2G12, and 447-52D show varying degrees of cross-clade neutralizing breadth and potency ([@bib40]; [@bib11]; [@bib15]; [@bib111]; [@bib139], [@bib140]; [@bib135]; [@bib160]).

Analysis of first-generation anti--HIV-1 neutralizing antibodies revealed several unusual features, such as long Ig heavy chain complementarity determining regions (CDRH3s), self-reactivity, and high levels of somatic hypermutation (SHM; [@bib49]; [@bib151]). However, the number of antibodies analyzed was limited. Therefore, it was difficult to establish the generality of each of these observations, their significance for vaccine development, or which, if any, of these features was required for the development of bNAbs ([@bib16]).

Epitope mapping of the first-generation antibodies identified four major sites of vulnerability on Env: (1) the CD4-binding site (CD4bs; [@bib3]; [@bib15]); (2) the membrane proximal external region (MPER; [@bib96]; [@bib135]; [@bib160]); (3) a glycan patch on gp120 that includes the N332 glycan ([@bib140]); and (4) the tip of the V3 loop ([@bib40]). The availability of information on bNAb epitopes led to the suggestion that immunogens could be designed to mimic these targets and elicit bNAbs ([@bib102]; [@bib16]; [@bib116]; [@bib133]). However, as mentioned above, all attempts to do so were disappointing because none of the specifically designed immunogens elicited broad or potent cross-clade neutralizing antibodies.

Why eliciting bNAbs is so difficult remained unclear until the introduction of single B cell antibody cloning ([@bib120],[@bib121]; [@bib138]).

Single-cell antibody cloning {#s04}
============================

The introduction of single-cell anti--HIV-1 antibody cloning methods in 2008 ([@bib121]) and their subsequent use by numerous laboratories led to the discovery of a new generation of potent bNAbs that reinvigorated efforts to produce active and passive HIV-1 vaccines. Moreover, it enabled several observations that helped explain why eliciting anti--HIV-1 bNAbs is so difficult and suggested alternative approaches to vaccine development.

Anti--HIV-1 antibodies were initially cloned from mRNA extracted from individual B cells isolated based on their ability to bind to Env ([@bib120],[@bib121]). Later, similar methods were adapted to clone antibodies from primary B cell cultures and EBV-transformed B cells starting with PG9 and PG16 ([@bib147]).

The antibody cloning experiments de-convoluted the serologic activity in individuals that developed broadly neutralizing responses. Although no two individuals were identical, serum-neutralizing activity could be accounted for by a single or a combination of different antibodies targeting different sites of vulnerability on the HIV-1 Env ([@bib120], [@bib122]; [@bib147], [@bib148]; [@bib153], [@bib154]; [@bib7]; [@bib59]; [@bib95]; [@bib36]; [@bib77]; [@bib22]; [@bib131]; [@bib81]; [@bib128]). Structural and biochemical analysis of the new antibodies enabled a detailed molecular understanding of the new epitopes and revealed novel vaccine targets on Env. Whereas there were only four known neutralizing epitopes in 2009, we now know of additional targets of bNAbs: (1) a trimer-dependent epitope at the apex of the Env spike; (2) the interface of gp120 and gp41; and (3) a recently identified epitope comprising the N88 glycan and the fusion peptide at the N terminus of gp41 ([@bib74]; [@bib151]; [@bib13]; [@bib73]; [@bib142]). Moreover, some of these epitopes can be recognized by a variety of different mechanisms. For example, there are at least three unique molecular approaches that antibodies use to target the CD4bs of gp120 ([@bib159]; [@bib43]).

The antibody cloning experiments uncovered hundreds of new antibodies, several of which were two to three orders of magnitude more potent in virus neutralization than those that were available before 2009 ([@bib13]). When injected into monkeys, several of these second-generation bNAbs, including 3BNC117, VRC01, 10-1074, and PGT121, protected from simian-HIV (SHIV) infection at concentrations that might be achievable by immunization ([@bib91]; [@bib126]). In addition, single injections of antibodies protected macaques from weekly low-dose challenge with SHIV for up to 23 wk ([@bib35]).

Most important for the vaccine effort, single-cell antibody cloning experiments produced key insights that led to novel approaches to vaccine design. One fundamental observation that emerged was that anti--HIV-1 antibodies, including those that have low or absent levels of neutralizing activity, are generally more somatically mutated than non--HIV-1--specific antibodies cloned from the same B cell pool ([Fig. 1](#fig1){ref-type="fig"}; [@bib120]). Although high levels of SHM are observed in some chronic infections, they are far lower than in HIV-1--specific antibodies ([@bib9]). bNAbs are a subset of anti--HIV-1 antibodies that display the greatest potency and neutralization breadth and, as such, conform to this more general rule that antibodies to HIV-1 are extensively mutated ([@bib147]; [@bib156]; [@bib122]; [@bib70]; [@bib77]; [@bib22]; [@bib131]; [@bib14]; [@bib154]).

![**Requirement for sequential immunization.** (A) Panel illustrates the finding that HIV-1 antibodies are highly somatically mutated. (B) Panel shows that germline-reverted antibodies fail to bind to most HIV-1 antigens. (C) Panel illustrates the observation that HIV-1 and bNAbs develop in sequence over time. (D) Panel shows the results of knock-in mouse immunization experiments that showed that multiple immunogens would be required for bNAb development.](JEM_20161765_Fig1){#fig1}

Somatic mutations are introduced into antibody genes by activation induced cytidine deaminase (AID), an enzyme that converts cytosine to uracil resulting in a DNA mismatch that is repaired by one of a variety of different pathways to produce mutations. The same lesions can also produce deletions, insertions, and even chromosome translocations, but these are far less frequent than somatic mutations ([@bib110]; [@bib68]). AID poses a threat to the genome, and its expression is therefore primarily restricted to dividing B cells in the dark zone of the germinal center ([@bib146]). In addition, its catalytic activity is limited such that it only introduces 1 base pair change per 1,000 nucleotides per cell division ([@bib89]). This relative low rate of mutation limits deleterious off-target effects while permitting efficient selection for individual mutations that increase affinity, accounting in part for the relatively low level of mutation found in most human antibodies. Accumulating up to 100 mutations in the 300 nucleotide IgV~H~ region (as seen in some bNAbs) would require hundreds of cell division cycles, far more than might be expected from an average round of B cell selection ([@bib146]; [@bib37], [@bib38]; [@bib136]).

One way to account for the high level of mutation in anti--HIV-1 antibodies is by multiple rounds of germinal center selection ([@bib120]; [@bib145]; [@bib71]). According to this hypothesis, an antibody that develops to the predominant circulating virus selects against sensitive viral variants, resulting in the emergence of a closely related but antibody-resistant viral variant. The antibody-resistant HIV-1 variant then elicits an additional round of immunoglobulin hypermutation, followed by germinal center--based selection for B cells synthesizing antibodies that recognize the new HIV-1 variant. However, production of the new antibody would lead to selection against the new HIV-1 variant. This cycle of HIV-1 selection and escape from antibody, followed by additional rounds of germinal center B cell selection would be repeated on multiple occasions over time, eventually resulting in the emergence of highly mutated HIV-1--specific antibodies. This scheme is consistent with, and potentially helps explain, the observation that emergence of bNAbs differs from typical humoral immune responses in that they take longer to develop and have more somatic mutations. Moreover, it is in keeping with longstanding ideas about continuing mutation and selection by both the immune system and the virus ([@bib109]; [@bib149]; [@bib16]).

Although prime and boost vaccine regimens with heterologous Env proteins ([@bib72]; [@bib27]; [@bib93]; [@bib45]) failed to elicit bNAbs, strong support for the idea that bNAbs are elicited sequentially came from prospective studies of several HIV-1--infected individuals who developed bNAbs. In these studies, antibodies and HIV-1 viruses were obtained concurrently from several different time points. The data showed that the initial antibody response was strain specific and targeted the earliest dominant HIV-1 virus in circulation. The first wave of antibodies selected against the concurrently circulating virus, resulting in the emergence of viral variants that were resistant to the initial antibody response. As expected based on the high levels of mutation seen in HIV-1 antibodies, the antibody-resistant virus elicited a secondary antibody response that once again selected for viruses resistant to all antibodies in circulation. Over a period of years, this process was repeated multiple times, giving rise to antibodies to several neutralization-sensitive sites on HIV-1 that eventually accounted for the observed serologic neutralization activity. These elegant prospective studies pioneered by Haynes and colleagues, and confirmed by others ([@bib7], [@bib8]; [@bib77]; [@bib22]; [@bib4]; [@bib154]; [@bib81]), are entirely consistent with the idea that eliciting bNAbs might require a combination of sequential immunogens that target specific precursor B cells and foster prolonged germinal center responses that select for the essential bNAb mutations ([Fig. 1](#fig1){ref-type="fig"}; [@bib120]; [@bib19]; [@bib100]; [@bib158]; [@bib50]; [@bib95]; [@bib62], [@bib63]; [@bib71]; [@bib86]; [@bib24]).

Another key finding that came out of the antibody cloning experiments was that somatic mutations are generally required for neutralizing activity of anti--HIV-1 antibodies ([@bib156]; [@bib94], [@bib95]; [@bib158]; [@bib7]; [@bib122]; [@bib56]; [@bib70]; [@bib130]; [@bib68]). Once again, bNAbs, the subset of anti--HIV-1 antibodies displaying the greatest neutralization breadth, conform to this general rule ([@bib156]; [@bib122]; [@bib70]). With the few exceptions obtained from prospective studies where the founder viruses could be identified, the predicted germline precursors of anti--HIV-1 antibodies, including bNAbs, failed to bind to all tested Envs ([Fig. 1](#fig1){ref-type="fig"}). Thus, the immunogens that had been used in an attempt to elicit bNAbs in past vaccine trials likely failed to bind to B cells expressing bNAb precursors and were therefore unable to initiate bNAb maturation. This insight led to the proposal that initiation of bNAb maturation would require immunogens that are selected for or specifically designed to bind to B cells expressing bNAb germline precursors ([@bib120]; [@bib156]; [@bib19]; [@bib71]).

In conclusion, finding high-level somatic mutation and its critical role in bNAb activity led to the proposal that singular antigens would not be able to elicit bNAbs ([@bib120]). It was evident that immunization to achieve this goal would require a novel vaccine scheme modeled on the natural infection in that it would require sequential immunization starting with antigens specifically selected or designed to activate B cells expressing germline precursors of bNAbs ([@bib120]; [@bib19]; [@bib94]; [@bib50]; [@bib71]).

Germline-targeting antigens {#s05}
===========================

The observation that most recombinant Env proteins are unable to engage the inferred germline version of bNAbs motivated rational immunogen design to engineer Env proteins that do so. These efforts were facilitated by the availability of inferred germline antibodies that were used to screen libraries of Env variants and test the engineered proteins ([@bib156]; [@bib56]; [@bib62]; [@bib86]). Several different approaches to germline B cell targeting are currently being evaluated.

One approach is to design antigens that specifically target a single bNAb B cell lineage. The potential advantage of this approach is that it focuses the immune response on restricted epitopes on Env that might otherwise be poorly immunogenic. Examples of this approach are the engineered outer domains eOD-GT6 and eOD-GT8 ([@bib62], [@bib63]) and the 426c gp140 TM4DV1-3 protein ([@bib87]). These proteins were selected for binding to germline VRC01 class antibodies and were shown to activate Ca^2+^ flux in vitro by B cell lines expressing inferred VRC01 class precursor antibodies. These new antigens differ from previously available Env antigens in that they make the rather narrow CD4bs more available, in part by removing a glycosylation motif at amino acid position 276--278 that normally interferes with the binding of most antibodies to this site. Although this first generation of germline-targeting antigens represents a conceptual advance, their spectrum of activity is limited to a specific subset of CD4bs antibodies, and therefore their use as single immunogens may be suboptimal. For example, the affinity of individual germline VRC01 class antibodies, such as VRC01 and 3BNC60 for eOD-GT8, differs, as does the ability of this antigen to elicit responses from B cells expressing the two antibodies ([@bib24]; [@bib64]; and see section Mice expressing inferred germline antibodies). Whether immunization with this first generation of germline-targeting antigens can in fact expand the limited group of VRC01 precursors in humans remains to be determined ([@bib64]; [@bib132]; [@bib137]).

Another group of engineered germline-targeting antigens is based on the native-like SOSIP Env trimers ([@bib5]; [@bib113]). One potential advantage of engineering germline-targeting antigens based on native-like Env trimers is that several independent antibody target sites could be modified to activate germline precursors of more than just one bNAb lineage. An additional advantage of SOSIP Env trimers is that they are stabilized in the prefusion conformation and reduce exposure of nonneutralizing epitopes ([@bib67]; [@bib80]).

Similar to the CD4bs antigens described above (eOD-GT6, eOD-GT8, and 426c gp140 TM4DV1-3), PGT121 germline-targeting SOSIP immunogens are being developed based in part on the molecular characterization of putative intermediates in bNAb development and on selection of candidate antigens using germline-reverted antibodies ([@bib130]; [@bib33], [@bib34]; [@bib119]; [@bib134]). Although these initial SOSIP immunogens were designed to elicit a single bNAb lineage, they could be further engineered to target additional bNAb lineages.

Finally, naturally arising Env variants obtained from transmitted founder viruses that elicited bNAbs represent another approach to germline antibody targeting. This idea was enabled by prospective studies of individuals that develop bNAbs, but it has yet to be tested in experimental animal models ([@bib7]; [@bib77]; [@bib22]; [@bib154]; [@bib81]).

Testing HIV-1 vaccine concepts in genetically engineered mice {#s06}
=============================================================

Individual B cells carry unique receptors that are randomly assembled by V(D)J recombination leading to a highly diverse repertoire of naive B cells that can potentially respond to nearly any foreign antigen. In the case of HIV-1 Env, this means that humoral immune responses typically involve production of antibodies to several different epitopes ([@bib23]), the vast majority of which, including the immunodominant epitopes, are strain specific or nonneutralizing. Although a diverse response covering many different epitopes would be optimal in a vaccine regimen, the complexity of such a response makes it difficult to analyze.

One way to simplify the problem and focus on B cell responses to a specific epitope is to introduce pre-rearranged VDJ~H~ and VJ~L~ into the mouse genome by gene targeting ([@bib39]). Expression of the knock-in antibody transgenes induces allelic exclusion and thereby shuts off V(D)J recombination of endogenous Ig genes ([@bib98]). Thus, mice that carry pre-rearranged Ig genes express primarily the receptor of interest. In addition to combining the knock-in VDJ~H~ and VJ~L~ to produce the fully intact antibody, the two genes can also be studied independently, in which case the introduced transgene pairs with endogenous mouse IgK/L or IgH chains, respectively. There are several advantages to the latter, including a diverse repertoire of B cells with varying specificities that begins to approach the normal repertoire in that it contains a more limited number of bNAb precursors. An important limitation to this approach is that it is restricted to genetically engineered mice. However, a major advantage is that immunology is better studied in the mouse than any other experimental model system, facilitating detailed analysis of immunization experiments.

Mice expressing inferred germline antibodies {#s07}
============================================

Initially, available knock-in mice carrying first-generation bNAbs were suboptimal for vaccine studies because they expressed the mature antibodies, and not their inferred germline precursors. Moreover, mice carrying antibodies targeting the membrane proximal domain, 2F5 and 4E10, showed severe abnormalities in B cell development because of self-reactivity ([@bib143], [@bib144]; [@bib25]; [@bib99]).

Knock-in mice expressing the inferred germline version of bNAbs have recently been generated and used to test new vaccine concepts ([@bib24]; [@bib63]; [@bib10]; [@bib30]; [@bib88]; [@bib137]; [@bib157]). The initial experiments were performed in mice that carry the inferred germline IgH of 3BNC60 or VRC01, both of which belong to the VRC01 class of anti-CD4bs antibodies ([@bib24]; [@bib63]; [@bib88]). This group of antibodies shares several features, including the same IgV~H~ germline gene, V~H~1-2\*02, which makes critical contacts with Env through CDRH2. They show high levels of somatic mutations, and their heavy chain is always paired with Ig light chains with short (5--amino acid long) CDRL3s ([@bib150]). The short CDRL3 is rarely found in mouse or human Ig light chains but is an essential feature of these antibodies because it avoids antibody clashes with the V5 region of Env ([@bib86]).

Immunization of germline 3BNC60 or VRC01 knock-in mice with germline-targeting antigens, eOD-GT8, 426c gp140 TM4ΔV1-3, or eOD-GT6, produced antibody responses of which a fraction were specific for the CD4bs ([@bib24]; [@bib63]; [@bib88]; [@bib137]). Single-cell antibody cloning experiments revealed that the germline-targeting immunogens selectively expanded B cell clones expressing the 3BNC60 or VRC01 heavy chains paired with mouse IgL containing 5--amino acid--long CDRL3s. However, the mice differed in that selection of the 5--amino acid CDRL3 IgL was far more efficient in one of the VRC01 germline knock-in strains than in the other two ([@bib24]; [@bib63]; [@bib137]). This difference may be caused by a lower affinity of the antigens for germline 3BNC60 and by differences in the way in which the two VRC01 knock-in mice were produced ([@bib63]; [@bib137]). Irrespective of these differences, and as might be expected, none of the antibodies elicited by immunization with highly modified germline-targeting Env antigens bound to native-like Env antigens or neutralized HIV-1 ([Fig. 1](#fig1){ref-type="fig"}).

In contrast to the germline-targeting antigens, native-like antigens failed to induce responses in the VRC01 or 3BNC60 germline IgH knock-in mice ([Fig. 1](#fig1){ref-type="fig"}). Thus, germline-targeting antigens were essential to activate naive B cells and select for specific characteristics associated with VRC01 class bNAb development. However, the germline-targeting antigens available to date fail to induce neutralizing responses, and they have a narrow spectrum of activity in that only a very limited number of CD4bs-directed bNAb precursors can be activated by these antigens.

Similar results were obtained with knock-in mice that carry the inferred germline IgH and IgL chain corresponding to PGT121, a bNAb targeting the V3-glycan epitope on the Env spike ([@bib30]). The germline sequence of PGT121 was based on the CDRH3 sequence of the least mutated clonal relative 10-996 of the same original donor ([@bib95]). Native-like SOSIP antigens predictably failed to induce antibody responses in these mice. In contrast, a specifically designed germline-targeting antigen induced B cell responses, although once again immunization with this single immunogen was not sufficient to produce neutralizing antibodies ([@bib30]; [@bib134]).

Finally, the VRC01-class germline-targeting eOD-GT8 antigen was also used to immunize transgenic mice carrying human Ig heavy and light chain loci, which gives rise to a diverse repertoire of B cells expressing human antibodies ([@bib132]). Although not measured directly, it was estimated that the precursor frequency for VRC01 class B cells in these mice was on the order of 0.2--1.3 cells per mouse. After immunization, B cells binding to the antigen in a CD4bs-specific manner were obtained by cell sorting. 1% of these antigen-binding memory B cells identified by flow cytometry expressed VRC01-class antibodies, or 28 cells in 17 mice, or 1.6 cells per mouse in the 29% of the mice that responded. Whether this represents a significant expansion that can be further induced to develop into bNAbs remains to be determined.

In conclusion, the initial studies in knock-in mice showed that naive B cells expressing inferred germline versions of bNAbs can be activated by specifically selected or engineered germline-targeting antigens but not by native-like Env trimers. These results, together with the observation that most Envs do not engage germline bNAb precursors, may in part explain why the Env immunogens used in vaccines have failed to elicit neutralizing responses to date.

Sequential immunization in genetically engineered mice {#s08}
======================================================

As discussed in the previous section, immunization of germline antibody knock-in mice with germline-targeting immunogens did not lead to the development of neutralizing antibodies. Moreover, it became evident upon uncovering the prevalence and essential nature of anti--HIV-1 antibody mutation ([@bib94], [@bib95]; [@bib158]; [@bib7]; [@bib122]; [@bib70]; [@bib130]) and the natural progression of bNAb development ([@bib109]; [@bib149]; [@bib77]; [@bib22]; [@bib154]; [@bib81]) that immunization to reproduce this phenomenon and elicit bNAbs may require a sequential immunization approach using immunogens that would shepherd the immune response toward bNAbs ([@bib120], [@bib122]; [@bib19]; [@bib100]; [@bib158]; [@bib50]; [@bib95]; [@bib62]; [@bib70],[@bib71]; [@bib86]).

This idea was initially tested using a synthetic intermediate 3BNC60 knock-in mouse that carried the mature heavy chain of 3BNC60 paired with random germline mouse light chains ([@bib24]). Whereas germline-targeting antigens elicited antibodies that were only capable of neutralizing HIV-1 viruses lacking the glycan at position 276, immunization with a native-like trimer elicited antibodies with the ability to neutralize heterologous tier 2 HIV-1 strains bearing an intact glycosylation site at position N276 ([@bib24]). Cross-clade neutralizing activity elicited after immunization with the native-like trimer was associated with selection for a highly restricted set of Ig light chains that exclusively expressed the required short CDRL3 of 5 amino acids and showed key mutations that correlated with neutralization breadth. Thus, B cells bearing inferred germline precursors could only be activated by germline-targeting immunogens, but these immunogens did not elicit bNAbs, even when used to immunize mice bearing synthetic intermediates. In contrast, native-like immunogens failed to stimulate B cells bearing inferred germline precursors but were necessary to elicit neutralizing antibodies from B cells expressing the synthetic intermediate antibody ([@bib24]).

These initial experiments established that a combination of different immunogens would be necessary to elicit bNAbs; however, they were limited to a single epitope on Env, they failed to uncover a protocol that elicited bNAbs from germline precursors, and they did not achieve the exceptionally high levels of mutation and neutralizing activity associated with bNAbs. Several of these limitations were subsequently overcome in more recent studies using knock-in mice carrying the inferred germline VRC01 and PGT121 antibodies ([@bib10]; [@bib30]; [@bib137]).

Two studies using mice carrying inferred germline precursors of VRC01 achieved high levels of mutation by sequential immunization starting with germline-targeting Env immunogens followed by boosting with a series of less modified Env immunogens ([@bib10]; [@bib137]). In both cases, the initial immunogen opens up the CD4bs by removing glycans that normally impede antibody access to this epitope. Subsequent immunogens sequentially reincorporate the native sequence. The resulting antibodies neutralized a group of HIV-1 isolates lacking the potential N-linked glycosylation site at position N276. However, the serum of these mice was unable to neutralize HIV-1 viruses that carry an intact potential N-linked glycosylation site at position N276, which includes 95% of all viruses in current databases ([@bib10]; [@bib137]). Two exceptional MAbs neutralized a wild-type virus grown in 293S cells, but these cells failed to incorporate more complex glycans into the virion. Thus, the critical problem of how to elicit CD4bs-directed antibodies that can evade the glycan at position N276 remains to be addressed.

In contrast to the VRC01 mice, sequentially immunized knock-in mice expressing both IgH and IgL of the germline PGT121 antibody developed serologic activity and MAbs that showed significant potency and breadth against heterologous tier 2 isolates ([Fig. 2](#fig2){ref-type="fig"}; [@bib30]). PGT121 germline knock-in mice were immunized with a germline-targeting immunogen, 10MUT, followed by a sequence of modified and native-like Env antigens ([@bib30]; [@bib134]). The 10MUT immunogen is based on BG505-SOSIP.664 but differs from it in that the antibody target site is exposed by the introduction of mutations removing glycans at positions N137 and N133, which increase its affinity for germline PGT121 antibody ([@bib33]; [@bib134]). Each additional immunogen in the sequence partially reverted these mutations, and the final step in the immunization protocol included a combination of different native-like SOSIP Env trimers. The precise sequence was determined by ELISAs on the serum of the immunized mice against a panel of candidate antigens, and the boosting immunogen was selected on the basis of serologic cross-reactivity. Thereby, each step in the immunization protocol introduced antigens with decreasing affinities for germline PGT121. The resulting protocol yielded high levels of SHM that recapitulated several key mutations found in human PGT121-like antibodies.

![**Linking sequential immunization to somatic mutation and bNAb development.** The figure illustrates the immunization scheme that led to bNAb development in mice that carry the PGT121 germline gene. The initial immunogen had the highest affinity for the germline-reverted antibody, and subsequent immunogens had decreasing affinities. Somatic mutation increased with immunization.](JEM_20161765_Fig2){#fig2}

In conclusion, sequential immunization with antigens designed to shepherd the antibody response toward bNAb development induced high levels of somatic mutation irrespective of the epitope targeted. These are the first results demonstrating that anti--HIV-1 bNAbs can be elicited by immunization. However, there are several caveats to consider---most importantly this was achieved in knock-in mice wherein there is limited B cell diversity. A more diverse immune system may fail to respond in the same way. For example, it was difficult to demonstrate enrichment for memory B cells expressing VRC01-like antibodies in mice that carry a diverse repertoire of human antibody genes (Kymab mice) immunized with eOD-GT8 ([@bib132]), possibly because of limiting naive precursor cells or competition for limiting T cell help by B cells carrying receptors for immunodominant epitopes ([@bib145]). In addition, none of the protocols reported to date elicit antibodies with the neutralization breadth and potency of the most potent bNAbs, nor do they take advantage of the fact that there are multiple neutralizing epitope targets on Env. Finally, although the sequential immunization experiments demonstrate that bNAbs can be elicited by immunization in these engineered systems, complex protocols involving immunization with multiple antigens in a specific sequence may not be practical in parts of the world where HIV-1 vaccines are most needed.

Passive vaccination {#s09}
===================

The demonstration by Kitasato and von Behring that antibodies can be used to prevent or treat infectious diseases was awarded a Nobel prize in 1901, and serum therapy was used extensively to treat and prevent serious infections in the first part of the 20th century. This form of therapy was largely abandoned with the advent of potent antibiotics and effective vaccines. However, starting 25 years ago, preclinical experiments performed in animal models showed that passively transferred neutralizing sera and first-generation monoclonal bNAbs are effective in protecting against HIV-1 infection ([@bib107]; [@bib83], [@bib84]; [@bib124]; [@bib1]; [@bib54]). Nevertheless, passive immunization with first-generation bNAbs was not pursued for HIV-1 prevention because of a combination of poor pharmacokinetic properties and limited overall breadth and potency ([@bib141]; [@bib66]; [@bib90]).

As might be expected from their greater neutralization breadth and potency against HIV-1 isolates in vitro and good pharmacokinetic properties in vivo, second-generation bNAbs are far more effective than first-generation bNAbs in preventing SHIV infection in macaques ([@bib125], [@bib126]; [@bib118]; [@bib35]; [@bib55]) and HIV-1 infection in humanized mice ([@bib105]; [@bib44]). A study of 60 macaques treated with one of five different bNAbs found that protection of 50% of the macaques against high-dose intravenous infection requires a relatively modest serum neutralizing titer of 1:100 ([@bib126]).

In contrast to the high-dose challenge model in macaques, humans are typically exposed to relatively low doses of HIV-1 by a mucosal route, and productive infection usually requires multiple exposures. [@bib35] modeled human infection by weekly intrarectal challenge with low doses of SHIV~AD8~ and found that a single passive bNAb infusion protected macaques for up to 23 wk. Protection was directly related to antibody concentration in serum and to antibody half-life. Overall, protection required serum antibody concentrations corresponding to the IC~80~ in TZM-bl assays. For example, VRC01, which is less potent than 3BNC117 but targets the same epitope on HIV-1 Env, protected macaques for an average of 8 wk, whereas 3BNC117 protected for an average of 13 wk. Increasing the half-life of VRC01 by adding a mutation to alter FcRN binding (VRC01-LS) nearly doubled protection from 8 to 14.5 wk ([@bib35]).

Although passive immunization is protective against SHIV challenge in these animal models, the mechanisms of protection are not fully understood. Fc receptor binding is required ([@bib51]; [@bib104]; [@bib47]). Two recent studies in rhesus macaques show that passive immunization with protective doses of bNAbs fails to completely sterilize SHIV infection at the site of viral challenge and that small amounts of viral RNA and DNA can be detected in distal tissues ([@bib55]; [@bib78]). Both studies suggest that in addition to blocking infection, early administration of bNAbs also eliminates small foci of viral replication and thereby limits dissemination and prevents productive infection ([@bib55]).

Human clinical trials with second-generation bNAbs have shown that VRC01 and 3BNC117 are generally safe and have half-lives of 2 and 2.5 wk, respectively ([@bib17]; [@bib75]; [@bib79]). Addition of the LS mutation that alters FcRN binding will likely increase the half-life by two- to fourfold ([@bib117]). Assuming that protection by antibody serum levels corresponds to the IC~80~ in TZM-bl assays, a single subcutaneous injection of the combination of 3BNC117-LS and 10-1074-LS could protect against over 90% of all strains for many months ([@bib35]). In theory, coverage could be further increased by addition of antibodies that target nonoverlapping sites on the HIV-1 Env, such as PGDM1400 ([@bib131]), or with more potent or broader antibodies ([@bib20]; [@bib32]; [@bib60]).

Conclusions {#s10}
===========

Significant advances in understanding the structural and immunological determinants of anti--HIV-1 antibody development enabled experiments using engineered mice and immunogens, which finally elicited bNAbs by vaccination. Concurrently, passive immunization studies using potent second-generation bNAbs were highly successful in protecting animals against HIV-1 infection. Antibodies are relatively expensive to manufacture compared with small molecule drugs; however, the low doses required for protection, their long half-life, ease of administration subcutaneously, and decreasing manufacturing costs all make a passive vaccine delivered on a quarterly or biyearly basis an attainable goal. In contrast, vaccination to produce modestly active bNAbs has only been achieved in antibody knock-in mice and by highly complex schemes involving multiple immunogens delivered in a specific sequential manner. Whether this can be achieved in physiologically relevant animal models or humans remains to be determined. Moreover, the potential challenges of developing, manufacturing, and delivering a multicomponent protein vaccine that has to be administered on a specific schedule and likely boosted on a regular basis may make this approach impractical in the near term. Thus, the alternative of a passively administered bNAb vaccine that can be developed rapidly and administered on a quarterly or biannual basis may be a realistic alternative to bridge the gap to a more conventional HIV-1 vaccine.
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